journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

journal
https://www.readbyqxmd.com/read/30016178/induction-chemotherapy-followed-by-cetuximab-radiotherapy-is-not-superior-to-concurrent-chemoradiotherapy-for-head-and-neck-carcinomas-results-of-the-gortec-2007-02-phase-iii-randomized-trial
#1
Lionnel Geoffrois, Laurent Martin, Dominique De Raucourt, Xu Shan Sun, Yungan Tao, Philippe Maingon, Joëlle Buffet, Yoann Pointreau, Christian Sire, Claude Tuchais, Emmanuel Babin, Alexandre Coutte, Frédéric Rolland, Marie-Christine Kaminsky, Marc Alfonsi, Michel Lapeyre, Marie Saliou, Cédric Lafond, Eric Jadaud, Bernard Gery, Ayman Zawadi, Jean-Marc Tourani, Cédric Khoury, Anne Rose Henry, Ali Hasbini, François Guichard, Christian Borel, Nicolas Meert, Pierre Guillet, Marie-Hélène Calais, Pascal Garaud, Jean Bourhis
Purpose Both concurrent chemoradiotherapy (CT-RT) and cetuximab radiotherapy (cetux-RT) have been established as the standard of care for the treatment of locally advanced squamous cell carcinoma of the head and neck. It was not known whether the addition of induction chemotherapy before cetux-RT could improve outcomes compared with standard of care CT-RT. Patients and Methods The current trial was restricted to patients with nonmetastatic N2b, N2c, or N3 squamous cell carcinoma of the head and neck and fit for taxotere, cisplatin, fluorouracil (TPF)...
July 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30016177/sirolimus-for-secondary-prevention-of-skin-cancer-in-kidney-transplant-recipients-5-year-results
#2
Jacques Dantal, Emmanuel Morelon, Lionel Rostaing, Eric Goffin, Anabelle Brocard, Isabelle Tromme, Nilufer Broeders, Véronique Del Marmol, Valérie Chatelet, Anne Dompmartin, Michèle Kessler, Andreas Serra, Günther F L Hofbauer, Nassim Kamar, Claire Pouteil-Noble, Jean Kanitakis, Adeline Roux, Evelyne Decullier, Sylvie Euvrard
Purpose Transplant recipients who develop cutaneous squamous cell carcinomas are at high risk for multiple subsequent skin cancers. Sirolimus has been shown to reduce the occurrence of secondary skin cancers, but no study included a follow-up exceeding 2 years. We extended at 5 years the TUMORAPA randomized trial of sirolimus-based immunosuppressive regimen versus calcineurin inhibitor-based immunosuppression. Methods Kidney transplant recipients receiving calcineurin inhibitors who had at least one cutaneous squamous cell carcinoma were randomly assigned to receive sirolimus as a substitute for calcineurin inhibitors (n = 64) or to maintain their initial treatment (n = 56)...
July 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30004815/sex-differences-in-efficacy-and-toxicity-of-systemic-treatments-an-undervalued-issue-in-the-era-of-precision-oncology
#3
Berna C Özdemir, Chantal Csajka, Gian-Paolo Dotto, Anna Dorothea Wagner
No abstract text is available yet for this article.
July 13, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30001169/creating-coherent-strategies-to-combat-the-crises-of-opioid-scarcity-and-abuse
#4
Andrew Hantel, Stacie Levine, Mark Siegler
No abstract text is available yet for this article.
July 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29989859/association-between-inflammatory-biomarker-c-reactive-protein-and-radiotherapy-induced-early-adverse-skin-reactions-in-a-multiracial-ethnic-breast-cancer-population
#5
Jennifer J Hu, James J Urbanic, L Doug Case, Cristiane Takita, Jean L Wright, Doris R Brown, Carl D Langefeld, Mark O Lively, Sandra E Mitchell, Anu Thakrar, David Bryant, Kathy Baglan, Jon Strasser, Luis Baez-Diaz, Glenn J Lesser, Edward G Shaw
Purpose This study examined an inflammatory biomarker, high-sensitivity C-reactive protein (hsCRP), in radiotherapy (RT)-induced early adverse skin reactions or toxicities in breast cancer. Patients and Methods Between 2011 and 2013, 1,000 patients with breast cancer who underwent RT were evaluated prospectively for skin toxicities through the National Cancer Institute-funded Wake Forest University Community Clinical Oncology Program Research Base. Pre- and post-RT plasma hsCRP levels and Oncology Nursing Society skin toxicity criteria (0 to 6) were used to assess RT-induced skin toxicities...
July 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29989858/analysis-of-plasma-epstein-barr-virus-dna-in-nasopharyngeal-cancer-after-chemoradiation-to-identify-high-risk-patients-for-adjuvant-chemotherapy-a-randomized-controlled-trial
#6
Anthony T C Chan, Edwin P Hui, Roger K C Ngan, Stewart Y Tung, Ashley C K Cheng, Wai T Ng, Victor H F Lee, Brigette B Y Ma, Hoi C Cheng, Frank C S Wong, Herbert H F Loong, Macy Tong, Darren M C Poon, Anil T Ahuja, Ann D King, Ki Wang, Frankie Mo, Benny C Y Zee, K C Allen Chan, Y M Dennis Lo
Purpose The contribution of adjuvant chemotherapy after chemoradiation therapy (CRT) in nasopharyngeal cancer (NPC) remains controversial. Plasma Epstein-Barr virus (EBV) DNA is a potential biomarker of subclinical residual disease in NPC. In this prospective, multicenter, randomized controlled trial, we used plasma EBV DNA to identify patients with NPC at a higher risk of relapse for adjuvant chemotherapy. Patients and Methods Eligible patients with histologically confirmed NPC of Union for International Cancer Control stage IIB to IVB, adequate organ function, and no locoregional disease or distant metastasis were screened by plasma EBV DNA at 6 to 8 weeks after radiotherapy (RT)...
July 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29989857/patient-reported-toxicity-during-pelvic-intensity-modulated-radiation-therapy-nrg-oncology-rtog-1203
#7
Ann H Klopp, Anamaria R Yeung, Snehal Deshmukh, Karen M Gil, Lari Wenzel, Shannon N Westin, Kent Gifford, David K Gaffney, William Small, Spencer Thompson, Desiree E Doncals, Guilherme H C Cantuaria, Brian P Yaremko, Amy Chang, Vijayananda Kundapur, Dasarahally S Mohan, Michael L Haas, Yong Bae Kim, Catherine L Ferguson, Stephanie L Pugh, Lisa A Kachnic, Deborah W Bruner
Purpose NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and health-related quality of life during treatment with standard pelvic radiation or intensity-modulated radiation therapy (IMRT) in women with cervical and endometrial cancer. Methods Patients were randomly assigned to standard four-field radiation therapy (RT) or IMRT radiation treatment. The primary end point was change in patient-reported acute GI toxicity from baseline to the end of RT, measured with the bowel domain of the Expanded Prostate Cancer Index Composite (EPIC)...
July 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29989856/risk-of-solid-cancer-after-treatment-of-testicular-germ-cell-cancer-in-the-platinum-era
#8
Harmke J Groot, Sjoukje Lubberts, Ronald de Wit, Johannes A Witjes, Jan Martijn Kerst, Igle J de Jong, Gerard Groenewegen, Alfons J M van den Eertwegh, Philip M Poortmans, Heinz-Josef Klümpen, Hetty A van den Berg, Tineke J Smilde, Ben G L Vanneste, Maureen J Aarts, Luca Incrocci, Alfons C M van den Bergh, Katarzyna Jóźwiak, Alexandra W van den Belt-Dusebout, Simon Horenblas, Jourik A Gietema, Flora E van Leeuwen, Michael Schaapveld
Purpose Testicular cancer (TC) treatment increases risk of subsequent malignant neoplasms (SMNs). It is unknown whether changes in TC treatment over time have affected SMN risk. Methods Solid SMN risk was evaluated in a multicenter cohort comprising 5,848 1-year survivors treated for TC before age 50 years between 1976 and 2007. SMN incidence was compared with cancer incidence in the general population. Treatment-specific risks were assessed using multivariable regression in a case-cohort design. Results After a median follow-up of 14...
July 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29989855/outcome-of-patients-with-early-stage-infradiaphragmatic-hodgkin-lymphoma-a-comprehensive-analysis-from-the-german-hodgkin-study-group
#9
Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A Eichenauer, Michael Fuchs, Karolin Behringer, Joseé M Zijlstra, Richard Greil, Jana Markova, Max S Topp, Julia Meissner, Andreas Neubauer, Christian Baues, Andreas Engert, Peter Borchmann, Bastian von Tresckow
Purpose The prognostic effect of isolated infradiaphragmatic involvement in Hodgkin lymphoma (HL) is controversial, and there are little data about patients treated with current therapies. Therefore, we performed a risk factor analysis to focus on isolated nodal infradiaphragmatic disease in patients treated within the German Hodgkin Study Group trials HD13 (clinical trial information: ISRCTN63474366) and HD14 (clinical trial information: ISRCTN04761296) for early-stage HL. Patients and Methods Characteristics and outcomes of patients who had infradiaphragmatic HL were compared with patients who had supradiaphragmatic disease...
July 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29989854/ado-trastuzumab-emtansine-for-patients-with-her2-mutant-lung-cancers-results-from-a-phase-ii-basket-trial
#10
Bob T Li, Ronglai Shen, Darren Buonocore, Zachary T Olah, Ai Ni, Michelle S Ginsberg, Gary A Ulaner, Michael Offin, Daniel Feldman, Todd Hembrough, Fabiola Cecchi, Sarit Schwartz, Nick Pavlakis, Stephen Clarke, Helen H Won, Edyta B Brzostowski, Gregory J Riely, David B Solit, David M Hyman, Alexander Drilon, Charles M Rudin, Michael F Berger, Jose Baselga, Maurizio Scaltriti, Maria E Arcila, Mark G Kris
Purpose Human epidermal growth factor receptor 2 ( HER2, ERBB2)-activating mutations occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial. Patients and Methods Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. The primary end point was overall response rate using Response Evaluation Criteria in Solid Tumors (RECIST) version 1...
July 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29985748/do-patients-with-advanced-cancer-have-the-ability-to-make-informed-decisions-for-participation-in-phase-i-clinical-trials
#11
Fay J Hlubocky, Greg A Sachs, Eric R Larson, Halla S Nimeiri, David Cella, Kristen E Wroblewski, Mark J Ratain, Jeffery M Peppercorn, Christopher K Daugherty
Purpose Patients with advanced cancer (ACPs) participating in phase I clinical trials inadequately understand many elements of informed consent (IC); however, the prevalence and impact of cognitive impairment has not been described. Patients and Methods ACPs enrolled onto phase I trials underwent neuropsychological assessment to evaluate cognitive functioning (CF) covering the following domains: memory (Hopkins Verbal Learning Test), executive functioning (Trail Making Test B), language (Boston Naming Test-Short Version and Controlled Oral Word Association Test), attention (Trail Making Test A and Wechsler Adult Intelligenence Scale-IV Digit Span), comprehension (Wechsler Adult Intelligence Scale-IV), and quality of life (Functional Assessment of Cancer Therapy-Cognitive Function)...
July 9, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29985747/clinical-and-genomic-characterization-of-treatment-emergent-small-cell-neuroendocrine-prostate-cancer-a-multi-institutional-prospective-study
#12
Rahul Aggarwal, Jiaoti Huang, Joshi J Alumkal, Li Zhang, Felix Y Feng, George V Thomas, Alana S Weinstein, Verena Friedl, Can Zhang, Owen N Witte, Paul Lloyd, Martin Gleave, Christopher P Evans, Jack Youngren, Tomasz M Beer, Matthew Rettig, Christopher K Wong, Lawrence True, Adam Foye, Denise Playdle, Charles J Ryan, Primo Lara, Kim N Chi, Vlado Uzunangelov, Artem Sokolov, Yulia Newton, Himisha Beltran, Francesca Demichelis, Mark A Rubin, Joshua M Stuart, Eric J Small
Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)-targeting therapy. We sought to characterize the clinical and genomic features of t-SCNC in a multi-institutional prospective study. Methods Patients with progressive, metastatic castration-resistant prostate cancer (mCRPC) underwent metastatic tumor biopsy and were followed for survival. Metastatic biopsy specimens underwent independent, blinded pathology review along with RNA/DNA sequencing...
July 9, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29985746/randomized-trials-of-proton-therapy-why-they-are-at-risk-proposed-solutions-and-implications-for-evaluating-advanced-technologies-to-diagnose-and-treat-cancer
#13
Justin E Bekelman, Andrea Denicoff, Jeffrey Buchsbaum
No abstract text is available yet for this article.
July 9, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29975624/progression-free-survival-as-a-surrogate-end-point-for-overall-survival-in-first-line-diffuse-large-b-cell-lymphoma-an-individual-patient-level-analysis-of-multiple-randomized-trials-seal
#14
Qian Shi, Norbert Schmitz, Fang-Shu Ou, Jesse G Dixon, David Cunningham, Michael Pfreundschuh, John F Seymour, Ulrich Jaeger, Thomas M Habermann, Corinne Haioun, Hervé Tilly, Hervé Ghesquieres, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Christopher R Flowers
Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed post-treatment would expedite clinical trial conduct and accelerate patient access to effective new therapies. Our objective was to formally evaluate progression-free survival (PFS) and PFS at 24 months (PFS24) as surrogate end points for OS in first-line DLBCL. Patients and Methods Individual patient data were analyzed from 7,507 patients from 13 multicenter randomized controlled trials of active treatment in previously untreated DLBCL, published after 2002, with sufficient PFS data to predict treatment effects on OS...
July 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29975623/randomized-trial-of-systemic-therapy-after-involved-field-radiotherapy-in-patients-with-early-stage-follicular-lymphoma-trog-99-03
#15
Michael MacManus, Richard Fisher, Daniel Roos, Peter O'Brien, Andrew Macann, Sidney Davis, Richard Tsang, David Christie, Bev McClure, David Joseph, Jayasingham Jayamohan, John F Seymour
Purpose Follicular lymphoma (FL) is curable by involved-field radiotherapy (IFRT) in < 50% of patients with stage I to II disease. We hypothesized that adding systemic therapy to IFRT would improve long-term progression-free survival (PFS). Patients and Methods A multicenter randomized controlled trial enrolled patients with stage I to II low-grade FL after staging computed tomography scans and bone marrow biopsies. 18 F-labeled fluorodeoxyglucose-positron emission tomography (PET) was not mandatory. Patients were randomly assigned to either arm A (30 Gy IFRT alone) or arm B (IFRT plus six cycles of cyclophosphamide, vincristine, and prednisolone [CVP])...
July 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29958038/reply-to-t-kurokawa-et-al
#16
Shveta S Motwani, Gary C Curhan
No abstract text is available yet for this article.
June 29, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29958037/managing-cancer-and-living-meaningfully-calm-a-randomized-controlled-trial-of-a-psychological-intervention-for-patients-with-advanced-cancer
#17
Gary Rodin, Christopher Lo, Anne Rydall, Joanna Shnall, Carmine Malfitano, Aubrey Chiu, Tania Panday, Sarah Watt, Ekaterina An, Rinat Nissim, Madeline Li, Camilla Zimmermann, Sarah Hales
Purpose Individuals with advanced cancer experience substantial distress in response to disease burden and impending mortality. Managing Cancer And Living Meaningfully (CALM) is a novel, brief, manualized psychotherapeutic intervention intended to treat and prevent depression and end-of-life distress in patients with advanced cancer. We conducted a randomized controlled trial to compare CALM with usual care (UC) in this population. Methods Patients with advanced cancer were recruited from outpatient oncology clinics at a comprehensive cancer center into an unblinded randomized controlled trial...
June 29, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29958036/risk-prediction-model-for-cisplatin-associated-acute-kidney-injury
#18
Tomohiro Kurokawa, Giichiro Tsurita, Tetsuya Tanimoto, Teppei Yamada, Soldano Ferrone
No abstract text is available yet for this article.
June 29, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29953304/face-to-face-and-internet-based-mindfulness-based-cognitive-therapy-compared-with-treatment-as-usual-in-reducing-psychological-distress-in-patients-with-cancer-a-multicenter-randomized-controlled-trial
#19
Félix Compen, Else Bisseling, Melanie Schellekens, Rogier Donders, Linda Carlson, Marije van der Lee, Anne Speckens
Purpose Mindfulness-based cognitive therapy (MBCT) has been shown to alleviate psychological distress in patients with cancer. However, patients experience barriers to participating in face-to-face MBCT. Individual Internet-based MBCT (eMBCT) could be an alternative. The study aim was to compare MBCT and eMBCT with treatment as usual (TAU) for psychological distress in patients with cancer. Patients and Methods We obtained ethical and safety approval to include 245 patients with cancer with psychological distress (≥ 11 on the Hospital Anxiety and Depression Scale) in the study...
June 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29949395/interim-futility-monitoring-assessing-immune-therapies-with-a-potentially-delayed-treatment-effect
#20
Edward L Korn, Boris Freidlin
Purpose Introduction of new immune therapies that may have a delayed beneficial effect necessitates re-evaluation of traditional clinical trial designs in oncology. A key design feature of randomized trials is interim futility monitoring, which allows stopping early if the accruing data convincingly demonstrate that the experimental treatment is detrimental or is unlikely to be shown superior to the standard treatment. The appropriateness of futility monitoring is frequently questioned when the effect of the experimental treatment may be delayed (eg, in trials of many immune agents)...
June 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"